Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 11 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.03 Insider Own12.34% Shs Outstand54.64M Perf Week0.00%
Market Cap147.53M Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float47.90M Perf Month-23.94%
Income-39.35M PEG- EPS next Q-0.22 Inst Own79.06% Short Float10.84% Perf Quarter-41.30%
Sales0.00M P/S- EPS this Y31.03% Inst Trans-2.67% Short Ratio6.34 Perf Half Y37.06%
Book/sh1.47 P/B1.84 EPS next Y-5.42% ROA-42.35% Short Interest5.19M Perf Year80.00%
Cash/sh1.90 P/C1.42 EPS next 5Y- ROE-71.82% 52W Range0.36 - 5.83 Perf YTD402.79%
Dividend Est.- P/FCF- EPS past 5Y-52.56% ROI-36.91% 52W High-53.69% Beta1.38
Dividend TTM- Quick Ratio46.22 Sales past 5Y0.00% Gross Margin- 52W Low643.80% ATR (14)0.26
Dividend Ex-Date- Current Ratio46.22 EPS Y/Y TTM74.66% Oper. Margin0.00% RSI (14)40.68 Volatility9.72% 9.42%
Employees29 Debt/Eq0.41 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price8.17
Option/ShortYes / Yes LT Debt/Eq0.41 EPS Q/Q68.71% Payout- Rel Volume5.11 Prev Close2.64
Sales Surprise- EPS Surprise-13.86% Sales Q/Q- EarningsMay 02 BMO Avg Volume818.56K Price2.70
SMA20-3.74% SMA50-19.30% SMA2009.87% Trades Volume3,896,369 Change2.27%
Date Action Analyst Rating Change Price Target Change
May-31-24Initiated Piper Sandler Overweight $10
May-14-24Initiated Stephens Overweight $8
Mar-01-24Initiated JMP Securities Mkt Outperform $7
May-30-23Upgrade SVB Securities Market Perform → Outperform $5 → $8
Dec-23-21Initiated H.C. Wainwright Buy $12
Jun-27-24 07:30AM
May-27-24 06:35AM
May-14-24 07:53AM
May-07-24 07:30AM
May-06-24 02:06PM
01:54PM Loading…
May-02-24 01:54PM
Apr-11-24 06:40AM
Apr-08-24 04:30PM
Mar-28-24 01:15PM
Mar-07-24 01:54PM
Mar-06-24 02:51PM
Mar-05-24 06:00PM
07:30AM Loading…
Mar-04-24 07:30AM
Feb-28-24 07:30AM
Feb-23-24 09:17AM
Feb-22-24 07:30AM
Jan-22-24 07:30AM
Jan-09-24 10:25AM
Jan-05-24 07:30AM
Nov-22-23 07:30AM
Nov-02-23 09:40AM
Sep-05-23 07:30AM
Aug-16-23 07:30AM
Aug-03-23 07:30AM
Jul-13-23 08:00AM
Jun-08-23 10:41PM
04:01PM Loading…
Jun-03-23 09:00AM
May-19-23 06:54AM
May-15-23 07:30AM
Apr-26-23 04:05PM
Apr-17-23 10:15AM
Mar-23-23 09:40AM
Mar-14-23 04:30PM
Mar-09-23 07:30AM
Mar-01-23 07:00AM
Feb-08-23 07:00AM
Jan-09-23 07:30AM
Jan-06-23 08:15AM
Nov-30-22 07:30AM
Nov-03-22 07:30AM
Aug-12-22 09:30AM
Aug-04-22 07:30AM
Aug-03-22 08:00AM
Jul-28-22 08:50AM
Jul-14-22 08:45AM
Jun-01-22 07:30AM
May-26-22 05:05PM
May-25-22 07:30AM
May-05-22 07:30AM
Apr-27-22 10:05AM
Mar-24-22 01:12PM
Mar-14-22 07:00AM
Mar-03-22 07:30AM
Mar-01-22 07:00AM
Jan-10-22 07:00AM
Jan-06-22 08:00AM
Jan-05-22 08:00AM
Dec-16-21 09:14AM
Nov-18-21 08:00AM
Nov-12-21 07:30AM
Oct-20-21 07:00AM
Oct-14-21 07:00AM
Sep-25-21 09:52AM
Sep-07-21 07:00AM
Aug-12-21 04:05PM
Aug-04-21 07:00AM
Jun-24-21 08:44PM
Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm's program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.